BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Victoza liraglutide: Postmarketing study data

A meta-analysis of 7 studies of Victoza, including the 6 Phase III LEAD trials, showed that a significantly greater proportion of patients with a baseline HbA1c of <=7.5% who received once-daily 1.8 mg Victoza achieved the American Association of Clinical Endocrinologists' recommended HbA1c goal of <=6.5% at...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >